Da Vinci Robotic-Assisted Surgery: 5 years of Health Technology Assessment Trends and Recommendations
Author(s)
Matthew Lien, MS, PharmD, Ana Yankovsky, MSc, Usha Kreaden, MSc.
Intuitive Surgical, Sunnyvale, CA, USA.
Intuitive Surgical, Sunnyvale, CA, USA.
Presentation Documents
OBJECTIVES: The da Vinci robotic-assisted surgery (RAS) system is a widely adopted technology with over 2.2 million procedures performed in 2023 alone and over 9,400 systems installed globally. Da Vinci RAS has been routinely assessed by HTA agencies for decades and remains a topic of interest by many agencies today. This analysis aims to examine trends and recommendations from HTAs of da Vinci RAS from the past 5 years.
METHODS: Publicly available HTA reports from 2020 to 2024 were identified via a targeted literature search. Sources searched included the International Network of Agencies for Health Technology Assessment/INAHTA database, as well as individual websites of HTA agencies from more than 20 countries. Snowballing was used to identify additional reports or agencies for review. Full text reports related to da Vinci RAS were included in the analysis. Reports were analyzed by year, country, specialty, procedure, and directional conclusions.
RESULTS: 38 individual reports from 16 different countries and 23 organizations were identified. Canada (26.3%) and the US (15.8%) produced the most reports, followed by European countries (34.2%), Asia-Pacific (18.4%), and Rest of World (5.2%). Eight different surgical specialties were included in the 38 reports, with general surgery (including colorectal), urology, gynecology (GYN), and thoracic representing the most assessed specialties. The most assessed procedures included prostatectomy, rectal resection, hysterectomy, and partial nephrectomy, followed by other GYN, colorectal, and urological procedures. Among these, 60.5% were classified as directionally positive, 34.2% as neutral, and 5.3% as negative.
CONCLUSIONS: Da Vinci RAS continues to be a prioritized technology for HTA amongst organizations globally, with more well-established da Vinci procedures accounting for majority of the indications assessed. Reports from the past 5 years have shown HTAs reaching favorable or neutral conclusions, likely due to a maturing clinical evidence base among procedures that are well adopted.
METHODS: Publicly available HTA reports from 2020 to 2024 were identified via a targeted literature search. Sources searched included the International Network of Agencies for Health Technology Assessment/INAHTA database, as well as individual websites of HTA agencies from more than 20 countries. Snowballing was used to identify additional reports or agencies for review. Full text reports related to da Vinci RAS were included in the analysis. Reports were analyzed by year, country, specialty, procedure, and directional conclusions.
RESULTS: 38 individual reports from 16 different countries and 23 organizations were identified. Canada (26.3%) and the US (15.8%) produced the most reports, followed by European countries (34.2%), Asia-Pacific (18.4%), and Rest of World (5.2%). Eight different surgical specialties were included in the 38 reports, with general surgery (including colorectal), urology, gynecology (GYN), and thoracic representing the most assessed specialties. The most assessed procedures included prostatectomy, rectal resection, hysterectomy, and partial nephrectomy, followed by other GYN, colorectal, and urological procedures. Among these, 60.5% were classified as directionally positive, 34.2% as neutral, and 5.3% as negative.
CONCLUSIONS: Da Vinci RAS continues to be a prioritized technology for HTA amongst organizations globally, with more well-established da Vinci procedures accounting for majority of the indications assessed. Reports from the past 5 years have shown HTAs reaching favorable or neutral conclusions, likely due to a maturing clinical evidence base among procedures that are well adopted.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
HTA15
Topic
Health Technology Assessment
Disease
No Additional Disease & Conditions/Specialized Treatment Areas